RedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Stock Performance

RedHill Biopharma stock traded down $0.04 during mid-day trading on Thursday, hitting $0.42. 1,453,669 shares of the company were exchanged, compared to its average volume of 3,378,427. The business has a fifty day moving average of $0.41 and a 200 day moving average of $0.48. RedHill Biopharma has a 1-year low of $0.26 and a 1-year high of $3.28.

Institutional Trading of RedHill Biopharma

An institutional investor recently raised its position in RedHill Biopharma stock. Gagnon Securities LLC lifted its holdings in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) by 32.1% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 118,360 shares of the biotechnology company’s stock after purchasing an additional 28,771 shares during the period. Gagnon Securities LLC owned 0.40% of RedHill Biopharma worth $63,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.